Marketing of Proteins and Peptide Pharmaceuticals

Marketing of Peptide, Proteins, Author: Sasan Nasoohi Function : Sales Manager Schering Plough Date : Nov 08 Presented to Ph.D. students of Faculty of Pharmacy of Tehran University

Proteins, eventually !! ,[object Object]

Proteins: disease and remedy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Proteins are drugs ! ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Peptide Pros and Cons ,[object Object],[object Object],[object Object],[object Object]

Origin of peptide products ,[object Object],[object Object],[object Object],[object Object],[object Object]

Peptide Pharmaceuticals ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Protein Therapeutics ,[object Object],[object Object],[object Object]

Major Brands > $ 1 Mln ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Iran Sales 4 month ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Cost-effectiveness ,[object Object],[object Object],[object Object],[object Object],[object Object]

Production Costs ,[object Object],[object Object],[object Object],[object Object]

What is PharmacoEconomics (PE)? Inputs Costs Health Care Outcomes

Pharmacoeconomics (PE) ,[object Object],[object Object],[object Object]

Costs ,[object Object],[object Object],[object Object]

Costs ,[object Object],[object Object],[object Object],Advantages: High Activity, High Specifity, Little unspecific binding to molecular structure other that desired target, Minimization of drug-drug interactions, Less accumulation in tissues, Lower toxicity, Often very potent, Biological diversity

Costs can be described in many ways ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Outcomes ,[object Object],[object Object],[object Object]

Most Active Developments ,[object Object],[object Object]

The top 10 biotechnology companies

Challenges ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Challenges ,[object Object],[object Object],[object Object],[object Object]

Current FDA Policy for approval of rDNA-derived Products ,[object Object],[object Object],[object Object],[object Object]

Determining the Degree of Similarity of Proteins ,[object Object],[object Object],[object Object],[object Object]

Product Comparability Testing ,[object Object],[object Object],[object Object],[object Object]

Pharmaceutical Equivalence (PE) ,[object Object],[object Object],[object Object],[object Object]

The ICH S6 Document ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Toxicology Testing of Biotech-Derived Agents: ICH-S6 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Feature of Benefit? ,[object Object],[object Object]

Marketing of Proteins and Peptide Pharmaceuticals

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Destaque

Destaque (20)

Semelhante a Marketing of Proteins and Peptide Pharmaceuticals

Semelhante a Marketing of Proteins and Peptide Pharmaceuticals (20)

Último

Último (20)

Marketing of Proteins and Peptide Pharmaceuticals